文献速递肝胆胰外科围术期管理与 ERAS

修订版R状态是新辅助治疗后胰腺癌切除术后生存的独立预测因素

The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
PubMed 文献 · Ann Surg · 2023-04-12

结果显示R0组中位总生存41.0个月,R1组20.6个月(P=0.002);R1是总生存(HR 1.56,95%CI 1.07-2.26)和无复发生存(HR 1.52,95%CI 1.14-2.0)的独立预测因素,且R1与局部复发显著相关。

要点

  • 新辅助治疗后胰腺癌R0(>1 mm)切除者中位总生存41.0个月,R1(≤1 mm)者20.6个月。
  • R1切除是总生存和无复发生存的独立不良预测因素。
  • R1切除与局部复发显著相关,与远处复发无关。

核心结论

  • 修订版R状态是新辅助治疗后胰腺导管腺癌切除术后生存和局部复发的独立预测因素。
  • 新辅助治疗后胰腺癌手术应以实现至少1 mm切缘的R0切除为主要目标。

研究设计与样本

  • 回顾性队列研究,从两个前瞻性维护的数据库识别接受新辅助治疗后行胰腺切除术的胰腺导管腺癌患者。

主要发现

  • R0切除272例(76.2%),R1切除85例(23.8%)。
  • R0组中位总生存41.0个月,R1组20.6个月(P=0.002)。
  • 附加辅助化疗后,R0组中位总生存44.8个月,R1组20.1个月(P=0.0032)。
  • R0组中位无复发生存17.5个月,R1组9.4个月(P<0.0001)。
  • R1切除与局部复发显著相关(P<0.0005),与远处复发无显著关联。

关键数值与推荐

  • R1切除对总生存的独立预测风险比HR为1.56(95%CI 1.07-2.26)。
  • R1切除对无复发生存的独立预测风险比HR为1.52(95%CI 1.14-2.0)。
  • 修订版R状态定义:R0为切缘>1 mm,R1为切缘≤1 mm。

临床怎么用

  • 新辅助治疗后胰腺癌切除术中应努力实现至少1 mm切缘的R0切除。
  • 术后病理报告应采用修订版R状态(1 mm)评估切缘,以指导预后判断。
  • R1切除患者局部复发风险高,术后辅助化疗仍可带来生存获益(R0组44.8个月 vs R1组20.1个月,P=0.0032)。

局限性

  • 回顾性研究设计,来自两个前瞻性数据库,可能存在选择偏倚。
  • 新辅助治疗方案异质(FOLFIRINOX、吉西他滨为基础方案及额外放疗比例不同)。
  • 原文未报告切缘评估的具体病理方法细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the oncological outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) who had an R 0 or R 1 resection based on the revised R status (1 mm) after neoadjuvant therapy (NAT). BACKGROUND: The revised R status is an independent prognostic factor in upfront-resected PDAC; however, the significance of 1 mm margin clearance after NAT remains controversial. METHODS: Patients undergoing pancreatectomy after NAT for PDAC were identified from 2 prospectively maintained databases. Clinicopathological and survival data were analyzed. The primary outcomes were overall survival (OS), recurrence-free survival (RFS), and pattern of recurrence in association with R 0 >1 mm and R 1 ≤1 mm resections. RESULTS: Three hundred fifty-seven patients with PDAC were included after NAT and subsequent pancreatic resection. Two hundred eight patients (58.3%) received FOLFIRINOX, 41 patients (11.5%) received gemcitabine-based regimens, and 299 individuals (83.8%) received additional radiotherapy. R 0 resections were achieved in 272 patients (76.2%) and 85 patients (23.8%) had R 1 resections. Median OS after R 0 was 41.0 months, compared with 20.6 months after R 1 resection ( P = 0.002), and even longer after additional adjuvant chemotherapy ( R 0 44.8 vs R1 20.1 months; P = 0.0032). Median RFS in the R 0 subgroup was 17.5 months versus 9.4 months in the R 1 subgroup ( P < 0.0001). R status was confirmed as an independent predictor for OS ( R 1 hazard ratio: 1.56, 95% CI: 1.07-2.26) and RFS ( R 1 hazard ratio: 1.52; 95% CI: 1.14-2.0). In addition, R 1 resections were significantly associated with local but not distant recurrence ( P < 0.0005). CONCLUSIONS: The revised R status is an independent predictor of postresection survival and local recurrence in PDAC after NAT. Achieving R 0 resection with a margin of at least 1 mm should be a primary goal in the surgical treatment of PDAC after NAT.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Leonhardt CS, Pils D, Qadan M, et al. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Ann Surg. 2023. PMID: 37042245. doi:10.1097/SLA.0000000000005874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。